Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

NCT06935838 on ClinicalTrials.gov · last registry update 2026-07-08

A small phase 2 — 12 participants, against a typical 110. The sponsor logged completion for 2 June 2026. Primary outcome, as filed: Change in Baseline Body Weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of Hawaii
Sponsor type: Other
Enrollment: 12
Started: 2025-11-12
Primary completion: 2026-06-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Baseline Body Weight

Conditions studied

Obesity and Overweight · HIV · Chronic Inflammation

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.